EUDA Health Holdings Ltd 6-K, filed Apr 24, 2025
EUDA Health Holdings Ltd (EUDA)
About this 6-K
EUDA Health Holdings Ltd filed this 6-K on April 24, 2025.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of April 2025
Commission File Number: 001-40678
EUDA Health Holdings Limited
(Exact Name of Registrant as Specified in its Charter)
60 Kaki Bukit Place, #03-01 Eunos Techpark, Singapore 415979
(Address of Principal Executive Offices and Zip Code)
Registrant’s telephone number, including area code: +65 6327 1110
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐
Appointment of Chief Operating Officer
On April 18, 2025, based on the recommendation of the Board of Directors’ Nominating Committee of EUDA Health Holdings Limited (“EUDA” or the “Company”), the Company’s Board approved and confirmed the appointment of Mr. John Ang Bian Guan as the Chief Operating Officer of the Company, effective April 21, 2025. Pursuant to an employment agreement dated April 18, 2025 between Mr. Ang and EUDA Health Pte Ltd, the Company has agreed to pay Mr. Ang SGD$10,000 (approximately US$7,610) per month. Mr. Ang’s employment agreement also contains certain non-compete and non-solicitation provision. A copy of Mr. Ang’s employment agreement is attached as Exhibit 10.1. The foregoing summary of the terms of Ms. Ang’s employment is subject to, and qualified in its entirely by, such document.
From March 2022 to December 2023, Mr. Ang was the Chief Operating Officer and Chief of Staff of International Cancer Specialists in Singapore. From May 2021 to March 2022, he was the Head of Group Service Operations at Singapore’s National University Hospital System. From January 2019 to January 2021, he was the Chief Operating Officer of Regency Specialist Hospital in Singapore. He brings 23 years of management expertise and with a proven track record in business processing operations, aviation, and healthcare. He possesses over a decade of experience in healthcare strategy and operations, having served in both public and private hospitals. He holds a Bachelor of Business Administration with Distinction from the Royal Melbourne Institute of Technology.
There is no family relationship between Mr. Ang and any other executive officer or director of the Company. There have been no related party transactions that would require disclosure under Item 404(a) of Regulation S-K under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and none are currently proposed between or among Mr. Ang, the Company, its executive officer, director, promoter or control person.
Agreement with Guangdong Key Lock Health Management
On April 22, 2025, CK Health Plus Sdn Bhd (“CK Health”), a wholly-owned subsidiary of EUDA and a direct seller of holistic wellness consumer products, entered into a collaboration agreement with Guangdong Key Lock Health Management Co., Ltd. (“Key Lock”), an authorized distributor of Guangdong Cell Biotech Co. Ltd. (“Guangdong Cell Biotech”). Pursuant to this collaboration agreement, CK Health will purchase from Key Lock certain stem cell therapy services offered by Guangdong Cell Biotech at certain pre-determined prices and market and sell these services in Singapore and Malaysia; and Key Lock will use its commercial endeavors to ensure proper stem cell services received by EUDA customers at one of Guangdong Cell Biotech’s treatment centers in China. This collaboration agreement is terminable by either party with one month’s notice of termination. A copy of collaboration agreement is attached as Exhibit 10.2. The foregoing summary of the terms of the collaboration agreement is subject to, and qualified in its entirely by, such document.
On April 24, 2025, the Company issued a press release relating to this collaboration agreement. A copy of this press release is attached hereto as Exhibit 99.1.
Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| Dated: April 24, 2025 | ||
| EUDA Health Holdings Limited | ||
| By: | /s/ Alfred Lim | |
| Name: | Alfred Lim | |
| Title: | Chief Executive Officer | |
Exhibit 10.1
Exhibit 10.2
Exhibit 99.1
EUDA Partners with Authorized Distributor of Guangdong Cell Biotech to Offer Stem Cell Therapies to Customers in Singapore and Malaysia
April 24, 2025 07:00 ET | Source: EUDA Health Holdings Ltd
SINGAPORE, April 24, 2025 (GLOBE NEWSWIRE) – EUDA Health Holdings Limited (“EUDA” or the “Company”) (NASDAQ: EUDA), a Singapore-based property management services provider and a leading non-invasive healthcare provider in Singapore and Malaysia, today announced an update to the potential strategic partnership, previously announced in December 2024, with Guangdong Cell Biotech Co. Ltd. (“Guangdong Cell Biotech”). Guangdong Cell Biotech is a prominent player in stem cell therapies and regenerative medicine in China. It develops autologous cell treatments and tailored medicines for various disorders.
Instead of the initially contemplated joint venture, the parties have adopted a commercial distribution arrangement structure that better aligns with their respective operational models and regional market dynamics.
On April 22, 2025, CK Health Plus Sdn Bhd (“CK Health”), a wholly-owned subsidiary of EUDA and a direct seller of holistic wellness consumer products, signed a collaboration agreement with Guangdong Key Lock Health Management Co., Ltd. (“Keylock”), an authorized distributor of Guangdong Cell Biotech. Pursuant to this collaboration agreement, CK Health will market and sell to EUDA customers in Singapore and Malaysia stem cell therapies provided by Guangdong Cell Biotech in China.
This revised structure builds upon the original strategic intent of the parties to collaborate, giving EUDA access to Guangdong Cell Biotech’s cutting-edge stem cell therapies and regenerative medicine.
“This commercial distribution structure showcases our strategy to diversify our business and revenue streams,” said Mr. Alfred Lim, CEO of EUDA. “Combining our mission to expand access to holistic healthcare solutions in Southeast Asia with Guangdong Cell Biotech’s established stem cell therapies, we aim to transform the health and wellness landscape in the region.”
About EUDA Health Holdings Limited
EUDA Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based property management services provider and a leading non-invasive healthcare provider in Singapore and Malaysia. Our mission is to transform the health and wellness landscape by leveraging cutting-edge technology to enhance non-invasive treatments and expand holistic healthcare access in Southeast Asia. We offer a diverse portfolio of innovative non-invasive wellness products and services, including bioenergy capsules and stem cell therapies, marketed under the CK Health brand in Malaysia and Singapore.
Forward Looking Statements
This document may contain forward-looking statements regarding risks and uncertainties. These statements usually use forward-looking words, such as the words “estimates,” “projected,” “expects,” “envisions,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions).These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside EUDA’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. You should not overly rely on forward-looking statements that are only applicable to the date of publication of this document. These forward-looking statements are based on information from EUDA and Guangdong Cell Biotech, as well as other sources that we believe are reliable. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Contact:
Christensen Advisory
Roger Hu
+852.2232.3968
roger.hu@christensencomms.com